NorthSea Therapeutics Strengthens Executive Team with Strategic CFO and CMO Appointments
• NorthSea Therapeutics appoints Melissa Bradford-Klug as CFO/CBO, bringing over 20 years of experience and $6 billion in financing track record to advance metabolic disease therapies.
• Dr. Sophie Jeannin joins as CMO, contributing extensive expertise in orphan and metabolic diseases from leadership roles at Summit Clinical Research and GENFIT.
• The company anticipates key clinical milestones with SEFA-1024 Phase 2a SHTG trial data in Q3 2025 and Orziloben Phase 2a IFALD interim results in H1 2026.
Iron Deficiency Anemia Therapeutics Market Shows Promise with Emerging Therapies
• The iron deficiency anemia (IDA) therapeutics market is expected to grow, with a market size of around USD 1,400 million in the 7MM in 2023.
• Emerging therapies like MPB-1514 (MegaPro Biomedical) and IDAX (Nemysis) show promise in improving treatment options for IDA patients.
• Clinical trials are underway to evaluate the efficacy of novel oral iron formulations like IHAT for increasing serum ferritin levels.
• Oral iron therapy remains the first-line treatment, but intravenous iron products like Monoferric (Pharmacosmos) offer alternatives.
© Copyright 2025. All Rights Reserved by MedPath